Suppliers / Cayman Pharma Sro

Cayman Pharma Sro

Czech Republic Updated 9 July 2026

Cayman Pharma Sro is an API manufacturer based in Czech Republic. It holds 7 active US drug master files across a filed portfolio of 7 molecules.

7
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Alprostadil SFDA (Saudi Arabia), US FDA 2
Bimatoprost US FDA 1
Epoprostenol US FDA 1
Latanoprost US FDA 1
Latanoprostene Bunod US FDA 1
Tafluprost US FDA 1
Travoprost US FDA 1

Also appears on these molecule pages

Questions about Cayman Pharma Sro

Does Cayman Pharma Sro hold a US DMF or a CEP?
Cayman Pharma Sro holds 7 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Cayman Pharma Sro make?
7 molecules are on record against Cayman Pharma Sro, including Alprostadil, Bimatoprost, Epoprostenol and Latanoprost. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Cayman Pharma Sro comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability